# N-Acetylcysteine in Adjunct to DBT for the Treatment of Self-Injurious Behavior in BPD

> **NCT00539188** · PHASE2 · TERMINATED · sponsor: **Yale University** · enrollment: 6 (actual)

## Conditions studied

- Borderline Personality Disorder
- Self-Injurious Behavior

## Interventions

- **DRUG:** N-Acetylcysteine
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT00539188
- **Lead sponsor:** Yale University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-09
- **Primary completion:** 2010-11
- **Final completion:** 2010-11
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** Study terminated due to poor subject compliance.
- **Last updated:** 2020-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00539188

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00539188, "N-Acetylcysteine in Adjunct to DBT for the Treatment of Self-Injurious Behavior in BPD". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT00539188. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*